Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluate Immunogenicity & Safety of a Single or Double-dose of the Pandemic Influenza Candidate Vaccine (GSK1562902A) Given Following a Two-administration Schedule (21 Days Apart) in Adults Over 60 Yrs

NCT00397215 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT00397215
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00397215 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluate Immunogenicity & Safety of a Single or Double-dose of the Pandemic Influenza Candidate Vaccine (GSK1562902A) Given Following a Two-administration Schedule (21 Days Apart) in Adults Over 60 Yrs
Lead sponsor
GlaxoSmithKline
Phase
Phase 2
Overall status
Completed
Start date
November 17, 2006
Completion date
September 14, 2009
Enrollment
437 (actual)
Sites
12

Conditions

As the registry lists them; a condition with its own page is linked.

influenza